Search the Newsreel

Voltaic Strategic Resources Clears 27.75m Expired Performance Rights

Voltaic Strategic Resources Seeks ASX Quotation for 8 Million New Shares

Voltaic Strategic Resources Completes Issuance of 10,967,359 Shares Following Performance Rights Conversion and Bundie Bore Stake Acquisition

Ariadne Australia Discloses Substantial Holder Interest Change for Lorona Pty Ltd

Papyrus Australia Secures $500,000 in Unsecured Loan Facilities from Four Investors

Earnings Flash (SSYS) Stratasys Ltd. Reports Q2 Revenue $137.6M, vs. FactSet Est of $138.5M

Stratasys Ltd. (SSYS) reported its Q2 revenue at $137.6 million, falling slightly short of FactSet's estimate of $138.5 million. The company also posted Q2 adjusted EPS of $0.03 per share, exceeding FactSet's estimate of $0.01. Stratasys reaffirmed its full-year 2026 earnings guidance, expecting revenue …

Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?

Key Points Earlier this month, AstraZeneca and Bristol Myers Squibb became the subject of merger rumors. Investors reacted negatively to the rumors, even if on paper such a deal would create an oncology-focused big pharma powerhouse worth around $400 billion. Considering regulatory uncertainty and …

How Investors Are Reacting To National Australia Bank (ASX:NAB) Leadership Shift Toward Tech, AI And Governance

Can Telstra Group (ASX:TLS) Turn Stronger Cash Earnings Into Lasting Momentum?

Papyrus Australia (ASX:PPY) Secures Further $500,000 Funding to Support Commercialisation and Contract Delivery

Papyrus Australia Plans Multi-Instrument Capital Raising on ASX

Stratasys (SSYS) Reports Q2: Everything You Need To Know Ahead Of Earnings

Stratasys Releases Q2 2026 Financial Results

Stratasys Ltd. (SSYS) reported a significant earnings beat in Q2 2026, with non-GAAP earnings per share of $0.03 against an estimated $0.01, despite a slight revenue decline to $137.6M. The company saw strong growth in its Aerospace and Defense segment and projects full-year adjusted …

SSYS|Stratasys Ltd|Price:8.955|Chg%:+0.115

Strata Critical Medical (SRTA) director Reginald Love sells 5,091 shares at $5.75

Strata Critical Medical, Inc. director Reginald Love sold 5,091 shares of Class A common stock at $5.75 per share on August 10, 2026. Following this transaction, his direct holdings in the company amount to 146,481 shares. The sale was reported in an open market …

AstraZeneca Stock And 2 Cash Flow Picks Trading Below Fair Value

Strauss Group (TASE:STRS) Stock Sees Profit Surge as Cash Flow Rebounds

(VST) Risk Channels and Responsive Allocation

This article analyzes Vistra Corp. (VST) using AI models to provide trading strategies. It highlights a near-term strong sentiment potentially challenging persistent mid and long-term weakness, with support currently being tested. The analysis includes position, momentum breakout, and risk hedging strategies, along with multi-timeframe …

Are Telstra shares a buy, hold, or sell after their full-year results, according to this expert?

Strattec CEO and CFO to present at Midwest IDEAS event Aug. 27

Strattec (Nasdaq: STRT) announced that its President & CEO, Jennifer Slater, and CFO, Matthew Pauli, will present and host investor meetings at the Midwest IDEAS Investor Conference on August 27, 2026. The presentation is scheduled for 9:15 a.m. Central Time and a live audio …

Mistras Group (MG) investor Aspasia Vahaviolos discloses 19.2% ownership stake

Aspasia Vahaviolos has disclosed a 19.2% ownership stake in Mistras Group (MG) through a Schedule 13G/A filing. Her holdings consist of 6,105,650 shares, including 1,794,839 shares held directly and 4,310,811 shares in a grantor retained annuity trust managed by her daughter. This significant stake …

Stratasys Q2 Earnings Call Highlights

Key Points Interested in Stratasys, Ltd.? Here are five stocks we like better. Q2 revenue was $137.6 million, up 3.7% sequentially but essentially flat year over year. Record consumables sales and 12.1% growth in Stratasys Direct offset a decline in system revenue. Management highlighted …

Telstra Stock Slips as A$1 Billion Buyback Meets Profit Miss

This article first appeared on GuruFocus. Telstra Group (TLGPY), Australia's largest telecommunications provider, slipped 0.5% in Thursday's early Australian trading. The market's message was pretty clear: another giant buyback was not enough. Telstra unveiled a fresh A$1 billion repurchase program, but annual attributable profit …

Wall Street Analysts Are Bullish on Top Healthcare Picks

Wall Street analysts are showing bullish sentiment towards two healthcare stocks: Orchestra BioMed Holdings (OBIO) and Adagene (ADAG). H.C. Wainwright reiterated a Buy rating for Orchestra BioMed with a $10.00 price target, while LifeSci Capital maintained a Buy rating for Adagene with an $8.00 …

Stratasys (SSYS) revenue holds near flat as H1 2026 losses and cash outflows rise

Stratasys (SSYS) reported nearly flat revenue for H1 2026, with a slight decrease of 0.3% in Q2 2026 revenue to $137.6 million, primarily due to longer sales cycles affecting systems revenue. The company experienced widened net losses, reaching $40.7 million for the first half …

Strata Critical Medical (SRTA) Q2 2026 Earnings Call Transcript

Stratasys (NASDAQ:SSYS) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings

Stratasys Ltd. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:SSYS) 2026-08-13

Stratasys Ltd. (NASDAQ: SSYS) published its slide deck in conjunction with its Q2 2026 earnings call. The company reported Q2 EPS of $0.03, beating estimates by $0.02, while revenue of $137.61M missed estimates by $872.25K, representing a 0.35% year-over-year decrease.

Insurance Australia Group Earnings: Australian Retail Strength Offset by Weak New Zealand

Can National Australia Bank (ASX:NAB) Hold Investor Attention as Banking Conditions Continue to Shift?

Vistra Corp (VST) News, Articles, Events & Latest Updates

This article compiles recent news and updates for Vistra Corp (VST), primarily focusing on its Q2 2026 earnings. Key highlights include beating EPS estimates, higher pricing and Lotus assets boosting EBITDA, but derivative losses impacting revenues. Analyst reactions, including Jim Cramer's positive sentiment, and …

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Orchestra BioMed Holdings, Inc. (OBIO) recently reported Q2 results showing revenues significantly below expectations, though statutory losses were in line with forecasts. Analysts have since updated their models, projecting a substantial 99% reduction in 2026 revenues and an increase in per-share losses, indicating a …

Q3 EPS Forecast for Strategic Education Lifted by Analyst

Stratasys Ltd. (SSYS) logs Q2 2026 loss but backs full-year guidance and Markforged deal

Stratasys Ltd. (SSYS) reported a Q2 2026 GAAP net loss of $16.9 million on essentially flat revenue of $137.6 million, but reaffirmed its full-year 2026 revenue guidance of $565–$575 million and Adjusted EBITDA of $25–$30 million. The company expects positive operating cash flow only …

Stratasys Ltd earnings beat by $0.02, revenue fell short of estimates

Stratasys Ltd (NASDAQ: SSYS) reported second-quarter EPS of $0.03, surpassing analyst estimates by $0.02, though its revenue of $137.6M fell short of the consensus estimate of $139.26M. The company provided guidance for FY 2026, projecting EPS between $0.09 and $0.14 and revenue between $565.00M …

Australian Clinical Labs Limited (ASX:ACL) Share Price Rises 1.72% as Stock Trades Within Daily Range